Conclusion.

30 June 2021 (17:17 - 17:20)

Organised by:

Video

Sign in to view the resources

About the speaker

Professor Stefan Anker

Charite University Hospital, Berlin (Germany)

5 More presentations in this session

Presentation thumbnail

Introduction: SGLT2 inhibitors beyond glycemic control.

Doctor S. Zieroth (Winnipeg, CA)

Presentation thumbnail

Impact of SGLT2 inhibitors on CV mortality, HF hospitalizations and clinical stability.

Professor M. Packer (Dallas, US)

Presentation thumbnail

Renal benefits of SGLT2 inhibitors in HF patients.

Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)

Presentation thumbnail

Effects of SGLT2 inhibitors on quality of life in HF.

Professor J. Butler (Dallas, US)

Presentation thumbnail

Safety of SGLT2 inhibitors with a focus on genital mycotic infections.

Professor G. Filippatos (Athens, GR)

Access the full session

Session thumbnail

SGLT2 inhibition in heart failure: what have we learned so far?

The Event

Heart Failure 2021

30 June 2021 17:17 CET

You may be interested in

Congress Presentation

Multimorbidity in heart failure: real world burden, treatment gaps, and healthcare utilization in germany

12 May 2026

Congress Presentation

Complications and time trends of ballon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension

20 March 2026

Congress Presentation

GLP-1 receptor agonists as an opportunity for patients with atherosclerotic cardiovascular disease as well as obesity in Germany

1 September 2025

Congress Presentation

Single pill regimen improves persistence and leads lo better clinical outcome compared to identical multi pill combination. Results of START, a German claims data analysis

30 August 2020

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources